SHUTTLE PHARMACEUTICALS HOLDINGS, INC. Increase (Decrease) in Interest Payable, Net
SHUTTLE PHARMACEUTICALS HOLDINGS, INC. (SHPH) reported Increase (Decrease) in Interest Payable, Net of -$15.06 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInInterestPayableNet · last filed 2026-03-31
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for the quarter ending 2024-09-30 was -$35.50K, a 214.27% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for the quarter ending 2024-06-30 was -$12.78K.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for the quarter ending 2024-03-31 was $33.22K, a 71.37% decline year-over-year.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for fiscal 2024 was -$15.06K, a 113.63% decline from fiscal 2023.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for fiscal 2023 was $110.45K, a 501.01% increase from fiscal 2022.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for fiscal 2022 was $18.38K, a 11386.25% increase from fiscal 2021.
- SHUTTLE PHARMACEUTICALS HOLDINGS, INC. increase (decrease) in interest payable, net for fiscal 2021 was $160.00.
| Period end | Increase (Decrease) in Interest Payable, Net 3 month | Increase (Decrease) in Interest Payable, Net 6 month | Increase (Decrease) in Interest Payable, Net 9 month | Increase (Decrease) in Interest Payable, Net 12 month | Increase (Decrease) in Interest Payable, Net 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$35.50K derived: sum of 2 quarters · filed 2026-03-31 | -$48.28K derived: sum of 3 quarters · filed 2026-03-31 | -$15.06K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$35.50K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$48.28K derived: sum of 2 quarters · filed 2025-11-13 | -$15.06K 10-Q · filed 2025-11-13 | -$11.18K derived: sum of 4 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$12.78K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $20.45K 10-Q · filed 2025-08-13 | $24.32K derived: sum of 3 quarters · filed 2025-08-13 | $55.39K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $33.22K 10-Q · filed 2025-05-08 | $37.10K derived: sum of 2 quarters · filed 2025-05-08 | $68.17K derived: sum of 3 quarters · filed 2025-05-08 | $27.63K derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $3.88K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $34.94K derived: sum of 2 quarters · filed 2025-02-26 | -$5.60K derived: sum of 3 quarters · filed 2025-02-26 | $110.45K 10-K · filed 2025-02-26 | |
| 2023-09-30 | $31.07K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$9.47K derived: sum of 2 quarters · filed 2024-11-13 | $106.58K 10-Q · filed 2024-11-13 | $119.23K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | -$40.54K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2024-09-04 | $75.51K 10-Q · filed 2024-09-04 | $88.16K derived: sum of 3 quarters · filed 2024-09-04 | $56.61K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2023-03-31 | $116.05K 10-Q/A · filed 2024-09-04 | $128.70K derived: sum of 2 quarters · filed 2024-09-04 | $97.15K derived: sum of 3 quarters · filed 2024-09-04 | $118.44K derived: sum of 4 quarters · filed 2024-09-04 | |
| 2022-12-31 | $12.65K derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-09-04 | -$18.90K derived: sum of 2 quarters · filed 2024-09-04 | $2.39K derived: sum of 3 quarters · filed 2024-09-04 | $18.38K 10-K/A · filed 2024-09-04 | -$13.18K 10-K · filed 2023-03-15 |
| 2022-09-30 | -$31.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$10.26K derived: sum of 2 quarters · filed 2023-11-13 | $5.73K 10-Q · filed 2023-11-13 | $5.62K derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | $21.29K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $37.28K 10-Q · filed 2023-08-14 | $37.17K derived: sum of 3 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $15.99K 10-Q · filed 2023-05-25 | $15.88K derived: sum of 2 quarters · filed 2023-05-25 | |||
| 2021-12-31 | -$110.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $160.00 10-K · filed 2023-03-15 | |||
| 2021-09-30 | $270.00 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Cellectar Biosciences, Inc. (CLRB) | United States | $0.020B | -1.03 |
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |